Published in Medical Patent Law Weekly, March 14th, 2012
The team tested a newly-created peptide, UN3, in pre-clinical models aimed to simulate impaired wound healing as is seen in patients with peripheral vascular diseases or uncontrolled diabetes. The peptide led to a 50% increase in blood vessel wall development, a 250% increase in growth...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.